LabMedica

Download Mobile App
Recent News Expo
Medica 2025
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quidel Introduces Savanna True Sample-to-Result Multiplex RT-PCR System at ECCMID 2022

By LabMedica International staff writers
Posted on 22 Apr 2022
Image: Savanna is a multiplex real-time PCR testing platform with simple sample-to-result operation (Photo courtesy of Quidel)
Image: Savanna is a multiplex real-time PCR testing platform with simple sample-to-result operation (Photo courtesy of Quidel)

Quidel (San Diego, CA, USA) introduced the Savanna true sample-to-result multiplex RT-PCR system at ECCMID 2022 which took place for the first time as a hybrid event both online and on-site in Lisbon, Portugal on 23 - 26 April 2022. ESCMID's yearly congress attracts over 14,000 participants. This year, the congress featured a hybrid format to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities to take part in the multifaceted program.

Savanna is a multiplex molecular platform that enables professional customers to analyze up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes. The Savanna system is a fully integrated, sample-to-result automated in-vitro diagnostic platform that performs real-time Polymerization Chain Reaction (PCR) tests by using the Savanna instrument and Savanna assay cartridges. After inserting the assay cartridge, the instrument performs sample and reagent preparation, nucleic acid extraction and amplification, real-time detection of RNA or DNA target sequence, and qualitative or quantitative result interpretation from a variety of sample types. The Savanna system is intended to aid in the diagnosis of related diseases. Quidel has received the CE Mark for its Savanna multiplex molecular analyzer, allowing the company to market and sell the Savanna system in Europe, as well as other countries that accept the CE Mark.

“The Savanna system’s small footprint features integrated sample prep combined with rapid real-time PCR amplification and detection technologies, making it a perfect fit for syndromic testing in hospitals and moderate-complexity labs, with the goal of eventually accessing physician offices, urgent care clinics and other point-of-care locations,” said Douglas Bryant, president and CEO of Quidel Corporation.

Related Links:
Quidel 

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Hematology

view channel
Image: Sickle cell disease patients with higher levels of RMVs, AMVs, and EMVs were found to have more severe disease (Photo courtesy of Adobe Stock)

Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients

Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more

Microbiology

view channel
Image: The rapid diagnostic test is being piloted across three UK hospitals (Photo courtesy of Imperial College Healthcare)

15-Minute Blood Test Diagnoses Life-Threatening Infections in Children

Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
GLOBE SCIENTIFIC, LLC